Wells Fargo & Company Kal Vista Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 15,932 shares of KALV stock, worth $185,289. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,932

Previous 14,559 9.43%

Holding current value

$185,289

Previous $172,000 8.72%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$10.35 - $12.49 $14,210 - $17,148	1,373 Added 9.43%	15,932 $187,000
Q1 2024 May 10, 2024	BUY	$11.07 - $16.04 $41,268 - $59,797	3,728 Added 34.42%	14,559 $172,000
Q4 2023 Feb 09, 2024	BUY	$7.58 - $12.25 $25,772 - $41,650	3,400 Added 45.75%	10,831 $132,000
Q3 2023 Nov 13, 2023	SELL	$8.95 - $11.35 $28,219 - $35,786	-3,153 Reduced 29.79%	7,431 $71,000
Q2 2023 Aug 15, 2023	BUY	$7.73 - $10.57 $38,858 - $53,135	5,027 Added 90.46%	10,584 $95,000
Q1 2023 May 12, 2023	BUY	$6.3 - $8.39 $27,197 - $36,219	4,317 Added 348.15%	5,557 $43,000
Q4 2022 Feb 13, 2023	SELL	$4.2 - $14.24 $33,688 - $114,219	-8,021 Reduced 86.61%	1,240 $8,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $2,629 - $4,493	-267 Reduced 2.8%	9,261 $134,000
Q2 2022 Aug 12, 2022	SELL	$8.16 - $15.1 $34,582 - $63,993	-4,238 Reduced 30.79%	9,528 $94,000
Q1 2022 May 16, 2022	SELL	$11.2 - $16.97 $86,721 - $131,398	-7,743 Reduced 36.0%	13,766 $203,000
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $725,371 - $1.07 Million	-58,687 Reduced 73.18%	21,509 $284,000
Q3 2021 Nov 15, 2021	SELL	$17.11 - $24.49 $104,559 - $149,658	-6,111 Reduced 7.08%	80,196 $1.4 Million
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $1.29 Million - $1.67 Million	55,998 Added 184.76%	86,307 $2.07 Million
Q1 2021 May 13, 2021	SELL	$14.69 - $42.57 $115,580 - $334,940	-7,868 Reduced 20.61%	30,309 $779,000
Q4 2020 Feb 09, 2021	SELL	$12.88 - $19.47 $149,459 - $225,929	-11,604 Reduced 23.31%	38,177 $726,000
Q3 2020 Nov 05, 2020	BUY	$9.83 - $13.99 $20,407 - $29,043	2,076 Added 4.35%	49,781 $627,000
Q2 2020 Aug 13, 2020	BUY	$6.75 - $12.89 $65,522 - $125,123	9,707 Added 25.55%	47,705 $578,000
Q1 2020 May 14, 2020	BUY	$5.8 - $18.56 $220,388 - $705,242	37,998 New	37,998 $292,000

Others Institutions Holding KALV

# of Institutions

121

Shares Held

48M

Call Options Held

71.8K

Put Options Held

26.3K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $286M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Kal Vista Pharmaceuticals, Inc. Transaction History